For a man in Riyadh seeking help for erectile dysfunction, the path to care is often a closed door. It can mean navigating a clinic waiting room, a hesitant conversation with a general practitioner, and the persistent weight of social stigma. Adam Health, a Riyadh-based startup founded in 2025, is building a digital health hub designed to open that door from the inside of a patient's home. With a $1 million pre-seed round from Saudi Angel Investors and Seedra Ventures, the company is stitching together tele-consultations, discreet medication delivery, and a proprietary wearable sensor, all orchestrated by an AI layer it hopes will become a continuous health companion for men across the Gulf [foradam.health, 2024] [F6S, 2024].
The Wedge of Discretion and Data
Adam Health's initial focus is deliberately narrow, targeting sexual performance conditions like erectile dysfunction and premature ejaculation. This is the clinical and cultural wedge. The platform promises an Arabic-first interface for tele-consultations, aiming to lower the barrier for men who might otherwise avoid care. The company's early traction signal is not revenue, but peer-reviewed clinical data. A 2025 prospective observational study published in a ScienceDirect journal detailed the use of the "ADAM wearable device" to alleviate psychogenic erectile dysfunction in men aged 18-40 [ScienceDirect, 2025]. The sensor, which discreetly tracks nocturnal penile tumescence (NPT) from home, provides objective biofeedback that can be crucial for diagnosing psychogenic versus physical causes of ED [talktoadam.com, 2026]. This hardware-and-data approach gives Adam Health a tangible, regulated asset to build upon, moving beyond a pure software telemedicine play.
An AI Layer for the Whole Man
The longer-term ambition, as presented at events like LEAP 2026, is to expand from sexual health into "whole-person wellness." The company describes an AI engine at the core of its platform, designed to connect a user's health history, lab results, consultation notes, medication regimens, and wearable data into an "intelligent care layer" [LEAP 2026, 2024]. The goal is a personalized, continuous guidance system that can flag trends, suggest preventive actions, and keep the patient engaged. For Adam Health, the AI is not positioned to replace physicians but to augment them, creating a more data-informed and longitudinal care relationship. The planned launch of operations in Saudi Arabia in May, with subsequent GCC expansion, will be the first real-world test of this integrated model [F6S, 2024].
Navigating a Crowded and Complex Field
The bet is substantial, and the landscape is not empty. Adam Health will need to differentiate itself on several fronts where established players and regional nuances create real friction.
- Regional competition. In the broader Middle East healthcare market, Adam Health will encounter large, integrated providers like Aster DM Healthcare and digital health platforms such as MedIQ and Cura. Their success will hinge on executing a more specialized, men's-health-native experience than these generalists can offer.
- Brand confusion. The name "Adam Health" is used by at least two other distinct entities: a men's health platform based in the UK and an AI health assistant project. The Saudi company's clear regional focus and regulatory footprint in the GCC should help mitigate this, but it remains a background noise factor in global search and awareness.
- Clinical integration. The promising sensor data from early studies must now be translated into a smooth, reimbursable care pathway. Integrating discreetly delivered medications and lab testing adds layers of operational and regulatory complexity that pure software startups avoid.
- The team's next chapter. Co-founders Omar Eljendy and Mohamed El-Sayed are now tasked with moving from concept and early funding to clinical operations and scaled user acquisition. Their public profiles show founder-led momentum but will need to be complemented by seasoned hires in medical affairs, supply chain logistics, and Gulf-based commercial strategy.
The Standard of Care Today
The patient population Adam Health seeks to serve is men, predominantly in Saudi Arabia and the GCC, dealing with conditions often shrouded in silence. Today, the standard of care is fragmented. It might involve a discreet online search for supplements, an awkward visit to a urologist accessed through a general referral, or simply no care at all due to embarrassment. Treatment often lacks continuity; a one-off prescription for phosphodiesterase-5 inhibitors like sildenafil may address a symptom but not the underlying psychological or physiological contributors. The ADAM sensor's focus on objective NPT measurement speaks directly to this diagnostic gap, offering a tool that has typically been confined to sleep labs. If Adam Health can successfully bundle this diagnostic clarity with accessible consultation and follow-up, it could redefine the entry point for men's healthcare in a region ripe for digital health innovation.
Sources
- [foradam.health, 2024] Adam | Saudi Arabia's First Digital Health Hub for Men | https://www.foradam.health/en
- [F6S, 2024] F6S profile for Adam Health (Jeddah) | https://www.f6s.com/company/adam-health
- [ScienceDirect, 2025] The Role of the ADAM Wearable Device in Alleviating Psychogenic Erectile Dysfunction in Men: A Prospective Observational Study | https://www.sciencedirect.com/science/article/pii/S2772973725007702
- [talktoadam.com, 2026] Adam Sensor | At-Home Men's Longevity & Biomarker Tracker | https://www.talktoadam.com/products/adam-sensor
- [LEAP 2026, 2024] LEAP 2026 Exhibitor Profile for Adam Health (Saudi Arabia) | https://connect.onegiantleap.com/event/leap2026/exhibitor/RXhoaWJpdG9yXzI0MjY5MjU=
- [ICS.org, 2026] ICS-EUS 2025 Abstract #229 The Role of the ADAM Wearable Device | https://www.ics.org/2025/abstract/229